Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metastasis Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAB40B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAB40B Recombinant Protein (Active GTPase & SOCS Box Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or Insect expressed. |
View RAB40B Products |
| Gene Delivery | RAB40B Promise-ORF / Lentivirus Full-length ORF for stable overexpression cell lines to study MMP transport. |
View RAB40B Products |
| Benchmark Ab | Anti-RAB40B Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and IP. |
View RAB40B Products |
| Validator | RAB40B siRNA Set For knockdown verification in migration assays. |
View RAB40B Products |
| Related Target A | CUL5 (Cullin-5) Essential E3 ligase scaffold partner forming the functional Cullin-RING ligase (CRL5) complex with RAB40B. |
View CUL5 Products |
| Related Target B | MMP9 (Matrix Metalloproteinase-9) Downstream effector; RAB40B-mediated transport of MMP9 drives extracellular matrix degradation. |
View MMP9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disruption of RAB40B-CUL5 Protein-Protein Interaction (PPI) | Co-expressed or highly purified RAB40B and CUL5 proteins available with verified sequence identity and high purity (>95%) for robust TR-FRET/AlphaLISA assays |
| GTP/GDP Binding Pocket Targetability | Nucleotide-free and nucleotide-loaded (GTPγS/GDP) states of RAB40B prepared under strict endotoxin-controlled conditions |
| Lack of Controls | High-affinity recombinant benchmark antibodies available for immunoprecipitation and localization verification |
| Off-Target Effects within Rab Family | Selectivity panels including closely related RAB40 isoforms (RAB40A, RAB40C) for counter-screening |
Live RAB40B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RAB40B therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum kinase inhibitors to targeted metastasis-blocking agents (migrastatics). As first-generation small-molecule inhibitors of intracellular trafficking reach preclinical validation, the next wave of R&D is targeting the unique SOCS-box-mediated E3 ligase recruitment capability of RAB40B, opening avenues for novel PROTAC designs and PPI disruptors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic/Biotech Consortiums | Triple-Negative Breast Cancer, NSCLC | In vitro binding assays (Requires high-purity RAB40B and CUL5 recombinant proteins) |
| PROTACs / Degraders | Targeted Protein Degradation (TPD) Pioneers | Metastatic Solid Tumors | Ubiquitination assays (Requires active E3 complex components and sequence-verified targets) |
| Gene Therapy / RNAi | Preclinical RNAi Developers | Advanced Epithelial Cancers | In vitro knockdown validation (Requires target-specific siRNA sets and stable overexpressing lentivirus) |